Skip to content
Menu

Viridian Therapeutics, Inc. VRDN

Full chart Compare
Set alert

Price alert · VRDN

All alert types
29.96 USD -1.48 (-4.71%)

Regular-session close

29.96 0.00 0.00%

After hours · Nov 20, 4:38 PM ET

29.87 Day range 31.75
13.18 52-week range 34.29
YTD
-3.73%
1 year
+1.66%

5D +0.95 (+3.15%)

3031FriMonTueWedThu31.12
Market cap
3.40B
Revenue (ttm)
26.31M
EPS (ttm)
-3.85
Shares out
113.56M
Forward P/E
-14.50
YTD return
-3.73%
1-year return
+1.66%
50-day average
23.35
200-day average
21.52
Enterprise value
2.96B
Volume
1.75M
Avg volume
2.13M
Open
31.12
Previous close
31.44
Day's range
29.87 – 31.75
52-week range
13.18 – 34.29
Beta
1.07
Analysts
Strong Buy
Price target
42.76 (+42.7%)
Earnings date
Feb 25, 2027

Key statistics

Price / sales
129.32
Price / book
7.05
Revenue growth
-63.50%
Free cash flow
-217.39M
Total cash
955.21M
Total debt
245.50M
Return on equity
-83.71%
Short % of float
15.56%

Fundamental scorecard

6 of 25 checks passed on VRDN’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
VRDN Revenue — quarterly 25.75M
VRDN Net income — quarterly -101.21M
VRDN EPS — quarterly -0.81

Earnings

VRDN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.72472———
Nov 4, 2026Sep 30, 2026-1.02-0.81+0.21+20.59%
Aug 6, 2026Jun 30, 2026-1.03-1.05-0.02-1.94%
May 5, 2026Mar 31, 2026-1.06-0.90+0.16+15.09%
Feb 26, 2026Dec 31, 2025-0.90-1.08-0.18-20.00%
Nov 5, 2025Sep 30, 2025-0.82-0.34+0.48+58.54%

Upgrades / downgrades

VRDN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 19, 2026B of A Securitiesinit—Buy
Nov 10, 2026WedbushmainOutperformOutperform
Nov 10, 2026Wells FargomainOverweightOverweight
Nov 5, 2026RBC CapitalmainOutperformOutperform
Nov 5, 2026Leerink PartnersmainOutperformOutperform
Nov 5, 2026Truist SecuritiesmainBuyBuy

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on VRDN — it syncs with the Stock Master app.

Insider holders

VRDN insider holders
InsiderRelationLatest transactionDateShares held
BEETHAM THOMAS WChief Operating OfficerConversion of Exercise of derivative securityMar 2, 202613,361
FAIRMOUNT FUNDS MANAGEMENT LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseMay 10, 20260
HARMON SETHChief Financial OfficerConversion of Exercise of derivative securityMar 2, 20267,790
MAHONEY STEPHEN FChief Executive OfficerConversion of Exercise of derivative securityMar 2, 202633,349
TOUSIGNANT JENNIFEROfficerConversion of Exercise of derivative securityAug 18, 20260
TRIPURANENI RADHIKAOfficerConversion of Exercise of derivative securityAug 13, 202640,000

Institution ownership

VRDN institution ownership
Holder% heldSharesValueReported
FMR, LLC15.42%17,509,137524.57MSep 29, 2026
Blackrock Inc.8.22%9,329,150279.50MSep 29, 2026
Paradigm Biocapital Advisors LP7.27%8,257,672247.40MSep 29, 2026
Bellevue Group AG6.26%7,109,318213.00MSep 29, 2026
Kynam Capital Management, LP5.41%6,148,000184.19MSep 29, 2026
Price (T.Rowe) Associates Inc4.51%5,123,569153.50MSep 29, 2026

Fund ownership

VRDN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.94%3,336,97099.98MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.28%2,590,08177.60MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.20%2,495,46174.76MSep 29, 2026
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund1.81%2,058,13061.66MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.32%1,500,00044.94MSep 29, 2026
T. Rowe Price Health Sciences Fund, Inc.1.27%1,447,74243.37MJun 29, 2026